| 10.06.2025 11:00 | HCM | Grant of Share Options and Awards under LTIP | RNS |
| 05.06.2025 11:27 | HCM | Hutchmed China kidney cancer therapy accepted for review in China | Alliance |
| 05.06.2025 07:00 | HCM | HUTCHMED and Innovent Announce NDA Acceptance | Reach |
| 02.06.2025 11:19 | HCM, AZN | Hutchmed reports progress in late-stage lung cancer trial | Alliance |
| 02.06.2025 07:00 | HCM | HUTCHMED Highlights SACHI Phase III Data at ASCO | Reach |
| 30.05.2025 09:30 | HCM | Total Voting Rights | RNS |
| 23.05.2025 07:00 | HCM | HUTCHMED Highlights Data to be Presented at ASCO | Reach |
| 13.05.2025 11:45 | HCM | AGM held on May 13, 2025 – Poll Results | RNS |
| 06.05.2025 14:14 | STJ, PHNX, MIDW | UK shareholder meetings calendar - next 7 days | Alliance |
| 02.05.2025 14:35 | WPM, RMV, PTSB | UK shareholder meetings calendar - next 7 days | Alliance |
| 24.04.2025 07:00 | HCM | HUTCHMED - Data to be Presented at AACR 2025 | Reach |
| 22.04.2025 10:53 | HCM, CLBS, ORCP | AIM WINNERS & LOSERS: Celebrus revenue to fall short of guidance | Alliance |
| 22.04.2025 08:32 | AZN, HCM | Hutchmed China completes enrolment for gastric cancer drug trial | Alliance |
| 22.04.2025 07:00 | HCM | HUTCHMED Completes Enrollment of Phase II Study | Reach |
| 07.04.2025 09:30 | HCM | 2024 Annual Report and Notice of AGM | RNS |
| 31.03.2025 10:30 | HCM | Extraordinary General Meeting – Poll Results | RNS |
| 21.03.2025 12:23 | HCM | IN BRIEF: Hutchmed China's Tazverik conditionally approved in China | Alliance |
| 21.03.2025 10:00 | HCM | NMPA Conditional Approval for TAZVERIK® | Reach |
| 20.03.2025 14:31 | AZN, HCM | IN BRIEF: Hutchmed highlights positive lung cancer test results | Alliance |
| 20.03.2025 09:30 | HCM | Retirement of Independent Non-executive Directors | RNS |
| 20.03.2025 07:00 | HCM | HUTCHMED Highlights Savolitinib SAVANNAH Phase II | Reach |
| 19.03.2025 13:45 | HCM | Publication of Form 20-F | Reach |
| 19.03.2025 12:08 | HCM | Hutchmed China celebrates kidney cancer treatment; swings to loss | Alliance |
| 19.03.2025 11:00 | HCM | 2024 Final Results and Business Updates | RNS |
| 19.03.2025 07:00 | HCM | Phase II/III Study of Fruquintinib and Sintilimab | Reach |
| 14.03.2025 09:30 | HCM | Adoption of the 2025 Long Term Incentive Plan | RNS |
| 14.03.2025 09:30 | HCM | Vesting of awards under Long Term Incentive Plan | RNS |
| 13.03.2025 09:30 | HCM | Notice of Extraordinary General Meeting | RNS |
| 12.03.2025 14:31 | SCT, PRU, NXQ | UK earnings, trading statements calendar - next 7 days | Alliance |
| 06.03.2025 10:00 | HCM | Completed Enrollment of Phase II Study | Reach |
| 05.03.2025 10:00 | HCM | Directorate Change | RNS |
| 03.03.2025 07:00 | HCM | Overseas Regulatory Announcement | RNS |
| 28.02.2025 15:00 | HCM | Overseas Regulatory Announcement | RNS |
| 19.02.2025 08:30 | HCM | Notice of Results | RNS |
| 28.01.2025 09:00 | HCM | Overseas Regulatory Announcement | RNS |
| 14.01.2025 12:07 | AZN, HCM | IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China | Alliance |
| 14.01.2025 07:00 | HCM | Full Approval for ORPATHYS in China | Reach |
| 02.01.2025 10:46 | AZN, HCM | Hutchmed China disposes of 45% stake in Shanghai joint venture | Alliance |
| 02.01.2025 07:01 | HCM | China NDA Acceptance for ORPATHYS and TAGRISSO | Reach |
| 02.01.2025 07:00 | HCM | Overseas Regulatory Announcement | RNS |
| 02.01.2025 07:00 | HCM | US$608m Divestment of Non-Core Joint Venture | RNS |
| 31.12.2024 08:30 | HCM | Appointment of Joint Corporate Broker | RNS |
| 30.12.2024 08:30 | HCM | Blocklisting Six Monthly Return | RNS |
| 13.12.2024 10:04 | AZN, HCM | IN BRIEF: Hutchmed to get Takeda milestone payment | Alliance |
| 03.12.2024 12:19 | HCM | Hutchmed China injection approval could be a "paradigm shift" | Alliance |
| 03.12.2024 10:00 | HCM | HUTCHMED and Innovent Announce ELUNATE Approval | Reach |
| 29.11.2024 08:30 | HCM | Total Voting Rights | RNS |
| 28.11.2024 10:32 | HCM | Continued Inclusion of ORPATHYS in China NRDL | Reach |
| 22.11.2024 10:00 | HCM | Hutchmed to get payment from Takeda as Fruzaqla launched in Japan | Alliance |
| 22.11.2024 07:00 | HCM | FRUZAQLA® Launched in Japan by Takeda | Reach |
| 20.11.2024 09:30 | HCM | Appointment of Independent Non-executive Director | RNS |
| 06.11.2024 07:00 | HCM | Clinical Data to be Presented at ASH and ESMO Asia | Reach |
| 31.10.2024 12:02 | HCM | Hutchmed China receives first milestone payment for Takeda drug sales | Alliance |
| 31.10.2024 08:30 | HCM | First Commercial Milestone Payment | Reach |
| 31.10.2024 08:30 | HCM | Total Voting Rights | RNS |
| 21.10.2024 09:30 | HCM | Vesting of awards under the LTIP | RNS |
| 16.10.2024 09:52 | AZN, HCM | TOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising results | Alliance |
| 16.10.2024 07:00 | HCM | SAVANNAH: clinically meaningful response rate | RNS |
| 10.10.2024 10:20 | HCM, CAML | AIM WINNERS & LOSERS: Windward rises; Hutchmed recovers | Alliance |
| 24.09.2024 08:49 | HCM | Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing | Alliance |
| 24.09.2024 08:00 | HCM | Japan Approval for FRUZAQLA | RNS |
| 09.09.2024 07:00 | HCM | Clinical Data to be Presented at ESMO and WCLC | Reach |
| 30.08.2024 12:24 | HCM | Hutchmed "disappointed" as it withdraws fruquintinib application | Alliance |
| 22.08.2024 09:30 | HCM | Standard form for notification of major holdings | RNS |
| 21.08.2024 09:30 | HCM | HUTCHMED to Host Expert Call to discuss ITP | Reach |
| 06.08.2024 10:00 | HCM | LTIP and Share Option Scheme | RNS |
| 31.07.2024 14:41 | HCM | Hutchmed confident of full year guidance for oncology and immunology | Alliance |
| 31.07.2024 12:00 | HCM | 2024 Interim Results and Business Updates | RNS |
